Malta - English - Medicines Authority

jv healthcare limited - fentanyl - solution for injection - fentanyl 50 µg/ml - anesthetics

Singapore - English - HSA (Health Sciences Authority)

alliance pharm pte. ltd. - fentanyl citrate 78.5mcg eqv to fentanyl base - injection, solution - fentanyl citrate 78.5mcg eqv to fentanyl base 50mcg

New Zealand - English - Medsafe (Medicines Safety Authority)

juno pharmaceuticals nz limited - fentanyl citrate 78.125 µg/ml equivalent to to 50 µg/ml of fentanyl - solution for injection - 50 mcg/ml - active: fentanyl citrate 78.125 µg/ml equivalent to to 50 µg/ml of fentanyl excipient: citric acid sodium chloride sodium citrate dihydrate sodium hydroxide as 2m solution for ph adjustment water for injection

Australia - English - Department of Health (Therapeutic Goods Administration)

bioq pharma pty ltd - ropivacaine hydrochloride monohydrate, quantity: 2.116 mg/ml (equivalent: ropivacaine hydrochloride, qty 2 mg/ml) - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; sodium hydroxide; water for injections - ropivacaine readyfusor (0.2% ropivacaine solution for injection) is indicated for: ? continuous peripheral nerve block infiltration for postoperative pain management in adults ? continuous wound infiltration for postoperative pain management in adults,(data for peripheral nerve block administered as a continuous peripheral infusion and for continuous wound infusion support the use for up to 48 hours only).

Australia - English - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - amikacin, quantity: 500 mg (equivalent: amikacin sulfate, qty 667.5 mg) - injection, solution - excipient ingredients: sulfuric acid; sodium metabisulfite; sodium citrate dihydrate; water for injections - amikacin sxp injection is indicated in the short-term treatment of serious infections caused by susceptible strains of gram negative bacteria (see microbiology).,staphylococcus aureus, including methicillin resistant strains, is the principal gram positive organism sensitive to amikacin.,the use of amikacin in the treatment of staphylococcal infections should be restricted to second line therapy, and should be confined to patients suffering from severe infections caused by susceptible strains of staphylococcus who have failed to respond or are allergic to other available antibiotics.,amikacin sxp injection is indicated in the treatment of neonatal sepsis when sensitivity testing indicates that other aminoglycosides cannot be used.,in certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin type drug maybe indicated because of the possibility of infections due to gram positive organisms such as streptococci or pneumococci. if concomitant treatment with a penicillin type drug is indicated, then the drugs should be administered separately because in vitro mixing of the two drugs causes inactivation of amikacin.,clinical studies have shown amikacin to be effective in treating bacteraemia, septicaemia including neonatal sepsis and serious infections of the respiratory tract, bones and joints, central nervous system, skin and skin structures (including those resulting from burns), intra-abdominal organs, postoperative infections and complicated and recurrent urinary tract infections, when caused by susceptible organisms.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - droperidol, quantity: 5 mg - injection, solution - excipient ingredients: mannitol; tartaric acid; sodium hydroxide; water for injections - anaesthesia droperidol droperidol lupin is indicated to produce tranquillisation and to reduce the incidence of nausea and vomiting in surgical and diagnostic procedures for premedication, induction, and as an adjunct in the maintenance of general and regional anaesthesia in neuroleptanalgesia in which droperidol lupin injection is given concurrently with a narcotic analgesic, to aid in producing tranquillity and decreasing anxiety and pain.,psychiatry the management of severe agitation, hyperactivity, or aggressiveness in psychotic disorders, including schizophrenic reaction and the manic type of manic depressive illness, or in disturbed states, such as some types of acute brain syndrome and in nonpsychotic acute excitation states.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - droperidol, quantity: 2.5 mg - injection, solution - excipient ingredients: mannitol; tartaric acid; sodium hydroxide; water for injections - anaesthesia droperidol lupin injection is indicated to produce tranquillisation and to reduce the incidence of nausea and vomiting in surgical and diagnostic procedures for premedication, induction, and as an adjunct in the maintenance of general and regional anaesthesia in neuroleptanalgesia in which droperidol lupin injection is given concurrently with a narcotic analgesic, to aid in producing tranquillity and decreasing anxiety and pain.,psychiatry the management of severe agitation, hyperactivity, or aggressiveness in psychotic disorders, including schizophrenic reaction and the manic type of manic depressive illness, or in disturbed states, such as some types of acute brain syndrome and in nonpsychotic acute excitation states.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - cisatracurium besilate, quantity: 211.05 mg (equivalent: cisatracurium, qty 157.5 mg) - injection, solution - excipient ingredients: benzenesulfonic acid; water for injections - cisatracurium injection is indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. it is used as an adjunct to general anaesthesia, or sedation in the intensive care unit.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - cisatracurium besilate, quantity: 14.07 mg (equivalent: cisatracurium, qty 10.5 mg) - injection, solution - excipient ingredients: benzenesulfonic acid; water for injections - cisatracurium injection is indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. it is used as an adjunct to general anaesthesia, or sedation in the intensive care unit.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - cisatracurium besilate, quantity: 28.14 mg (equivalent: cisatracurium, qty 21 mg) - injection, solution - excipient ingredients: water for injections; benzenesulfonic acid - cisatracurium injection is indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. it is used as an adjunct to general anaesthesia, or sedation in the intensive care unit.